Journal: BMC Nephrology

Article Title: The effect of SGLT2 inhibitor and HIF-PHI on the podocyte-specific molecules and cytoskeleton of diabetic podocytes

doi: 10.1186/s12882-025-04677-0

Figure Lengend Snippet: Effects of high glucose condition, Dapagliflozin, Roxadustat, and combined therapy on the distribution pattern of podocyte-specific molecules in cultured human podocytes. Representative images for nephrin, podocin, podocalyxin, and synaptopodin. Original magnification, ×630. Scale bar: 20 μm. NG, normal glucose (5 mM), HG, high glucose (25 mM), DAPA, Dapagliflozin (11 nM), ROXA, Roxadustat (30 µM)

Article Snippet: To establish podocyte injury in vitro, the differentiated podocytes were starved in medium containing 1% FBS for 12 h first and then subjected to different stimuli for 48 h: (1) normal glucose (NG, 5 mM); (2) high glucose (HG, 25 mM); (3) Dapagliflozin (1.1 nM or 11 nM, MedChemExpress); (4) Roxadustat (3 μM or 30 μM, MedChemExpress).

Techniques: Cell Culture

Journal: BMC Nephrology

Article Title: The effect of SGLT2 inhibitor and HIF-PHI on the podocyte-specific molecules and cytoskeleton of diabetic podocytes

doi: 10.1186/s12882-025-04677-0

Figure Lengend Snippet: Intracellular protein levels of podocyte-specific molecules in cultured human podocytes as determined by indirect immunofluorescence staining: ( A ) nephrin; ( B ) podocin; ( C ) podocalyxin; and ( D ) synaptopodin. Quantification of glomerular nephrin, podocin, podocalyxin, and synaptopodin level by semiquantitative computerized image analysis. Error bars denote standard error of mean (SEM); data were compared by one way analysis of variance (ANOVA) (overall p < 0.01); post hoc comparison between groups was performed by unpaired Student’s t test with adjustment for multiple comparison by the Benjamini-Hochberg procedure. NG, normal glucose (5 mM), HG, high glucose (25 mM), DAPA, Dapagliflozin (11 nM), ROXA, Roxadustat (30 µM)

Article Snippet: To establish podocyte injury in vitro, the differentiated podocytes were starved in medium containing 1% FBS for 12 h first and then subjected to different stimuli for 48 h: (1) normal glucose (NG, 5 mM); (2) high glucose (HG, 25 mM); (3) Dapagliflozin (1.1 nM or 11 nM, MedChemExpress); (4) Roxadustat (3 μM or 30 μM, MedChemExpress).

Techniques: Cell Culture, Immunofluorescence, Staining, Comparison

Journal: BMC Nephrology

Article Title: The effect of SGLT2 inhibitor and HIF-PHI on the podocyte-specific molecules and cytoskeleton of diabetic podocytes

doi: 10.1186/s12882-025-04677-0

Figure Lengend Snippet: Effect of high glucose condition, Dapagliflozin, Roxadustat, and combined therapy on the distribution of F-actin and α-actinin-4 in cultured human podocytes: ( A ) representative images for nephrin (green) and F-actin (red); yellow arrow: podocytes with F-actin relocation; white arrow: co-localization of nephrin and F-actin; ( B ) representative images for nephrin (green) and α-actinin-4 (red); arrows: podocytes with α-actinin-4 relocation. Nuclei were counterstained with DAPI (blue). Original magnification, ×630. Scale bar: 20 μm. The immunofluorescence staining intensities and quantification of glomerular ( C ) F-actin and ( D ) α-actinin-4 levels were measured by semiquantitative computerized image analysis. The intensities of all other treatments are normalized to NG levels. Error bars denote standard error of mean (SEM); data were compared by one way analysis of variance (ANOVA) (overall p < 0.01); post hoc comparison between groups was performed by unpaired Student’s t test with adjustment for multiple comparison by the Benjamini-Hochberg procedure. NG, normal glucose (5 mM), HG, high glucose (25 mM), DAPA, Dapagliflozin (11 nM), ROXA, Roxadustat (30 µM)

Article Snippet: To establish podocyte injury in vitro, the differentiated podocytes were starved in medium containing 1% FBS for 12 h first and then subjected to different stimuli for 48 h: (1) normal glucose (NG, 5 mM); (2) high glucose (HG, 25 mM); (3) Dapagliflozin (1.1 nM or 11 nM, MedChemExpress); (4) Roxadustat (3 μM or 30 μM, MedChemExpress).

Techniques: Cell Culture, Immunofluorescence, Staining, Comparison

Journal: Drug Design, Development and Therapy

Article Title: A Pharmacodynamic Evaluation of the Protective Effects of Roxadustat Against Hypoxic Injury at High Altitude

doi: 10.2147/DDDT.S390975

Figure Lengend Snippet: Effects of Different Doses of Roxadustat on the Survival Time of Mice. Error Bars Indicate SD (n=8/per Group \documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document} $$\bar x \pm {\rm{s}}$$ \end{document} )

Article Snippet: Roxadustat Capsules (Specification: 20 mg × 3 tablets, AstraZeneca Pharmaceutical Co., Ltd.); Normal Saline (500 mL: 4.5 g, Shijiazhuang Siyao Pharmaceutical Co., Ltd. Batch No. 2007122002); Heparin (Shanghai First Biochemical Pharmaceutical Co., Ltd.); Acetazolamide (Purity >98.0%, Shanghai Yuanye Biotechnology Co., Ltd. CAS#59-66-5); Rat TNF-α Elisa kit, Rat IL-6 Elisa kit, MDA kit (Nanjing Jincheng Institute of Bioengineering); SOD kit (Nanjing Jiancheng Institute of Biological Engineering); GSH Kit (Nanjing Jiancheng Institute of Biological Engineering); 4% Paraformaldehyde (500 mL, Wuhan Xaver Biotechnology Co., Ltd.).

Techniques: Control

Journal: Drug Design, Development and Therapy

Article Title: A Pharmacodynamic Evaluation of the Protective Effects of Roxadustat Against Hypoxic Injury at High Altitude

doi: 10.2147/DDDT.S390975

Figure Lengend Snippet: Comparison of Blood Gas Indexes in Each Group. Error Bars Indicate SD (n=6/per Group \documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document} $$\overline x\pm {\rm{s}}$$ \end{document} )

Article Snippet: Roxadustat Capsules (Specification: 20 mg × 3 tablets, AstraZeneca Pharmaceutical Co., Ltd.); Normal Saline (500 mL: 4.5 g, Shijiazhuang Siyao Pharmaceutical Co., Ltd. Batch No. 2007122002); Heparin (Shanghai First Biochemical Pharmaceutical Co., Ltd.); Acetazolamide (Purity >98.0%, Shanghai Yuanye Biotechnology Co., Ltd. CAS#59-66-5); Rat TNF-α Elisa kit, Rat IL-6 Elisa kit, MDA kit (Nanjing Jincheng Institute of Bioengineering); SOD kit (Nanjing Jiancheng Institute of Biological Engineering); GSH Kit (Nanjing Jiancheng Institute of Biological Engineering); 4% Paraformaldehyde (500 mL, Wuhan Xaver Biotechnology Co., Ltd.).

Techniques: Comparison

Journal: Drug Design, Development and Therapy

Article Title: A Pharmacodynamic Evaluation of the Protective Effects of Roxadustat Against Hypoxic Injury at High Altitude

doi: 10.2147/DDDT.S390975

Figure Lengend Snippet: Comparison of Blood Routine Indexes in Each Group. Error Bars Indicate SD (n=6/per Group \documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document} $$\overline x\pm {\rm{s}}$$ \end{document} )

Article Snippet: Roxadustat Capsules (Specification: 20 mg × 3 tablets, AstraZeneca Pharmaceutical Co., Ltd.); Normal Saline (500 mL: 4.5 g, Shijiazhuang Siyao Pharmaceutical Co., Ltd. Batch No. 2007122002); Heparin (Shanghai First Biochemical Pharmaceutical Co., Ltd.); Acetazolamide (Purity >98.0%, Shanghai Yuanye Biotechnology Co., Ltd. CAS#59-66-5); Rat TNF-α Elisa kit, Rat IL-6 Elisa kit, MDA kit (Nanjing Jincheng Institute of Bioengineering); SOD kit (Nanjing Jiancheng Institute of Biological Engineering); GSH Kit (Nanjing Jiancheng Institute of Biological Engineering); 4% Paraformaldehyde (500 mL, Wuhan Xaver Biotechnology Co., Ltd.).

Techniques: Comparison

Journal: Drug Design, Development and Therapy

Article Title: A Pharmacodynamic Evaluation of the Protective Effects of Roxadustat Against Hypoxic Injury at High Altitude

doi: 10.2147/DDDT.S390975

Figure Lengend Snippet: Effects of roxadustat on inflammatory factor and EPO in rats plasma. The content of IFN-γ ( A ), IL-6 ( B ), TNF-α ( C ) and EPO ( D ). Error bars indicate SD (n=6/per group).

Article Snippet: Roxadustat Capsules (Specification: 20 mg × 3 tablets, AstraZeneca Pharmaceutical Co., Ltd.); Normal Saline (500 mL: 4.5 g, Shijiazhuang Siyao Pharmaceutical Co., Ltd. Batch No. 2007122002); Heparin (Shanghai First Biochemical Pharmaceutical Co., Ltd.); Acetazolamide (Purity >98.0%, Shanghai Yuanye Biotechnology Co., Ltd. CAS#59-66-5); Rat TNF-α Elisa kit, Rat IL-6 Elisa kit, MDA kit (Nanjing Jincheng Institute of Bioengineering); SOD kit (Nanjing Jiancheng Institute of Biological Engineering); GSH Kit (Nanjing Jiancheng Institute of Biological Engineering); 4% Paraformaldehyde (500 mL, Wuhan Xaver Biotechnology Co., Ltd.).

Techniques: Clinical Proteomics

Journal: Drug Design, Development and Therapy

Article Title: A Pharmacodynamic Evaluation of the Protective Effects of Roxadustat Against Hypoxic Injury at High Altitude

doi: 10.2147/DDDT.S390975

Figure Lengend Snippet: Effects of roxadustat on SOD activity ( A ), GSH ( B ) and MDA ( C ) content in myocardial, renal, brain, lung and liver of hypoxic rats. Error bars indicate SD (n=6/per group).

Article Snippet: Roxadustat Capsules (Specification: 20 mg × 3 tablets, AstraZeneca Pharmaceutical Co., Ltd.); Normal Saline (500 mL: 4.5 g, Shijiazhuang Siyao Pharmaceutical Co., Ltd. Batch No. 2007122002); Heparin (Shanghai First Biochemical Pharmaceutical Co., Ltd.); Acetazolamide (Purity >98.0%, Shanghai Yuanye Biotechnology Co., Ltd. CAS#59-66-5); Rat TNF-α Elisa kit, Rat IL-6 Elisa kit, MDA kit (Nanjing Jincheng Institute of Bioengineering); SOD kit (Nanjing Jiancheng Institute of Biological Engineering); GSH Kit (Nanjing Jiancheng Institute of Biological Engineering); 4% Paraformaldehyde (500 mL, Wuhan Xaver Biotechnology Co., Ltd.).

Techniques: Activity Assay

Journal: Heliyon

Article Title: A critical review of Roxadustat formulations, solid state studies, and analytical methodology

doi: 10.1016/j.heliyon.2023.e16595

Figure Lengend Snippet: Physicochemical properties of Roxadustat.

Article Snippet: 14 , NCT02021318 , Drug: Roxadustat Drug: Darbepoetin alfa , Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa , • Anemia in Chronic Kidney Disease in non-dialysis Patients , • Astellas Pharma Europe B.V. •FibroGen • Astellas Pharma Inc.

Techniques: Molecular Weight, Solubility, Refractive Index

Journal: Heliyon

Article Title: A critical review of Roxadustat formulations, solid state studies, and analytical methodology

doi: 10.1016/j.heliyon.2023.e16595

Figure Lengend Snippet: Tablet formulations with some excipients.

Article Snippet: 14 , NCT02021318 , Drug: Roxadustat Drug: Darbepoetin alfa , Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa , • Anemia in Chronic Kidney Disease in non-dialysis Patients , • Astellas Pharma Europe B.V. •FibroGen • Astellas Pharma Inc.

Techniques:

Journal: Heliyon

Article Title: A critical review of Roxadustat formulations, solid state studies, and analytical methodology

doi: 10.1016/j.heliyon.2023.e16595

Figure Lengend Snippet: Metabolites of roxadustat.

Article Snippet: 14 , NCT02021318 , Drug: Roxadustat Drug: Darbepoetin alfa , Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa , • Anemia in Chronic Kidney Disease in non-dialysis Patients , • Astellas Pharma Europe B.V. •FibroGen • Astellas Pharma Inc.

Techniques:

Journal: Heliyon

Article Title: A critical review of Roxadustat formulations, solid state studies, and analytical methodology

doi: 10.1016/j.heliyon.2023.e16595

Figure Lengend Snippet: In-process impurities during the synthesis of Roxadustat.

Article Snippet: 14 , NCT02021318 , Drug: Roxadustat Drug: Darbepoetin alfa , Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa , • Anemia in Chronic Kidney Disease in non-dialysis Patients , • Astellas Pharma Europe B.V. •FibroGen • Astellas Pharma Inc.

Techniques:

Journal: Heliyon

Article Title: A critical review of Roxadustat formulations, solid state studies, and analytical methodology

doi: 10.1016/j.heliyon.2023.e16595

Figure Lengend Snippet: Related substance and possible In-process Impurity of Roxadustat.

Article Snippet: 14 , NCT02021318 , Drug: Roxadustat Drug: Darbepoetin alfa , Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa , • Anemia in Chronic Kidney Disease in non-dialysis Patients , • Astellas Pharma Europe B.V. •FibroGen • Astellas Pharma Inc.

Techniques:

Journal: Heliyon

Article Title: A critical review of Roxadustat formulations, solid state studies, and analytical methodology

doi: 10.1016/j.heliyon.2023.e16595

Figure Lengend Snippet: Mechanism of action of Roxadustat.

Article Snippet: 14 , NCT02021318 , Drug: Roxadustat Drug: Darbepoetin alfa , Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa , • Anemia in Chronic Kidney Disease in non-dialysis Patients , • Astellas Pharma Europe B.V. •FibroGen • Astellas Pharma Inc.

Techniques:

Journal: Heliyon

Article Title: A critical review of Roxadustat formulations, solid state studies, and analytical methodology

doi: 10.1016/j.heliyon.2023.e16595

Figure Lengend Snippet: Summary of all the 38 completed clinical trials related Roxadustat.

Article Snippet: 14 , NCT02021318 , Drug: Roxadustat Drug: Darbepoetin alfa , Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa , • Anemia in Chronic Kidney Disease in non-dialysis Patients , • Astellas Pharma Europe B.V. •FibroGen • Astellas Pharma Inc.

Techniques: Clinical Proteomics, Recombinant, Formulation, Comparison, Drug discovery

Journal: Journal of Medicinal Chemistry

Article Title: Focused Screening Identifies Different Sensitivities of Human TET Oxygenases to the Oncometabolite 2-Hydroxyglutarate

doi: 10.1021/acs.jmedchem.3c01820

Figure Lengend Snippet: Representative AlphaScreen IC 50 curves and correlation curves for inhibitors tested against TET1–3 CD and TET2 CDΔLCI . Plots for TET1 CD (A,B), TET2 CD (C,D), TET3 CD (E,F), and TET2 CDΔLCI (G,H) of selected inhibitors are shown. IOX1 (3, orange), NOG (5, pink), JIB-04 (14, gray), S -2HG (22, purple), R -2HG (23, black), ML324 (15, green), Vadadustat (13, red), IOX4 (8, yellow) and Panobinostat (21, blue). I-L AlphaScreen pIC 50 correlation plots for inhibitors for TET1–3 CD , TET2 CDΔLCI . Pearson correlation and Spearman coefficients were calculated for comparisons. Standard conditions: 5m C (1, 10 nM), ascorbate (100 μM), Fe(II) (10 μM), 2OG (10 μM), with TET1 CD (10 nM, 30 min incubation), TET2 CD (1 nM, 10 min incubation), TET3 CD (10 nM, 10 min incubation), or TET2 CDΔLCI (1 nM, 10 min incubation). n = 2–4, error given as ± StDev. IC 50 values are displayed in Table ; compound structures are given in Figure . Circled dots—other compounds from Table .

Article Snippet: IOX1, IOX2, ML324, KDMOAM25, succinate, fumarate, 2OG, dimethylpyridine-2,4-dicarboxylate, dimethyl 2-oxoglutarate, dimethyl succinate, dimethyl fumarate, and DMOG were purchased from Sigma-Aldrich, while IOX3, IOX4, Roxadustat, Vadadustat, Panobinostat, disodium 2 S/2R -hydroxyglutarate, and FG0041 were obtained from Cayman Chemical Company.

Techniques: Amplified Luminescent Proximity Homogenous Assay, Incubation

Journal: Journal of Medicinal Chemistry

Article Title: Focused Screening Identifies Different Sensitivities of Human TET Oxygenases to the Oncometabolite 2-Hydroxyglutarate

doi: 10.1021/acs.jmedchem.3c01820

Figure Lengend Snippet: Measurement and quantitation of TET2 CDΔLCI catalyzed oxidation of 5m C to 5hm C, 5f C, and 5ca C using the SPE-MS assay. (A) Representative SPE-MS spectra for TET2 CDΔLCI (0.8 μM) catalysis in the presence of 5m C 28 (1.0 μM) using the [M–3H] 3– charge state. Overlay of spectra from 0 min (black) and 5.57 min (red) time points showing sequential oxidation of 5m C to 5hm C (+16 Da relative to 5m C), 5f C (+14 Da relative to 5m C), and 5ca C (+30 Da relative to 5m C). (B) Corresponding time course displaying the relative abundance of 5m C 28 (green), 5hm C (orange), 5f C (purple), and 5ca C (red). (C,D) Representative IC 50 curves of IOX1 ( 3 , orange), NOG ( 5 , pink), JIB-04 ( 14 , gray), S -2HG ( 22 , purple), R -2HG ( 23 , black), IOX4 ( 8 yellow), Vadadustat ( 13 , red), ML324 ( 15 , green), and Panobinostat ( 21 , blue) tested with TET2 CDΔLCI (0.4 μM) and 5m C-DNA 28 (2.0 μM). Assays were quenched after 10 min (∼20–30% 5hm C product formation at a linear range ( R 2 : 0.99, Figure S6C )) to minimize formation of subsequent oxidative products 5f C and 5ca C. Standard conditions: 5m C-DNA ( 28 , 2.0 μM) and TET2 CDΔLCI (0.4 μM), ascorbate (200 μM), Fe(II) (50 μM), 2OG (10 μM). Data are plotted as mean ( n = 2–4) and error given as ± StDev.

Article Snippet: IOX1, IOX2, ML324, KDMOAM25, succinate, fumarate, 2OG, dimethylpyridine-2,4-dicarboxylate, dimethyl 2-oxoglutarate, dimethyl succinate, dimethyl fumarate, and DMOG were purchased from Sigma-Aldrich, while IOX3, IOX4, Roxadustat, Vadadustat, Panobinostat, disodium 2 S/2R -hydroxyglutarate, and FG0041 were obtained from Cayman Chemical Company.

Techniques: Quantitation Assay

Journal: Journal of Medicinal Chemistry

Article Title: Focused Screening Identifies Different Sensitivities of Human TET Oxygenases to the Oncometabolite 2-Hydroxyglutarate

doi: 10.1021/acs.jmedchem.3c01820

Figure Lengend Snippet: Small molecule inhibitors of TETs can reduce global 5hm C levels in cells. (A) Selected images of IF staining of Dox-inducible U2OS cells stably transfected with FLAG-tagged TET1 CD . An increase in FLAG (red) and 5hm C (green) staining, corresponding to overexpression of catalytically active TET1 CD , is observed only after Dox (1 mg mL –1 )-mediated induction. DAPI nuclear staining is in blue. Reduction in the 5hm C level is observed while FLAG staining is maintained when cells are treated with TET inhibitors (e.g., IOX4 8 ). This trend corresponds to observations with cells overexpressing a catalytically inactive TET1 CD mutant ( Figures S7–S9 ). (B) Representative EC 50 curves for IOX1 3 , IOX4 8 , JIB-04 14 , and DMOG 30 for Dox-induced U2OS cells overexpressing TET1 CD . All tested compounds reduce 5hm C levels in a dose-dependent manner. The 5hm C levels of Dox-induced and -uninduced control cells (1% DMSO) are indicated. Data are plotted as mean and error given as ± s.e.m ( n > 3000 cells). See Figures S9 and S11 for dosing data on TET1 CD MUT.

Article Snippet: IOX1, IOX2, ML324, KDMOAM25, succinate, fumarate, 2OG, dimethylpyridine-2,4-dicarboxylate, dimethyl 2-oxoglutarate, dimethyl succinate, dimethyl fumarate, and DMOG were purchased from Sigma-Aldrich, while IOX3, IOX4, Roxadustat, Vadadustat, Panobinostat, disodium 2 S/2R -hydroxyglutarate, and FG0041 were obtained from Cayman Chemical Company.

Techniques: Staining, Stable Transfection, Transfection, Over Expression, Mutagenesis, Control

Journal: Journal of Medicinal Chemistry

Article Title: Focused Screening Identifies Different Sensitivities of Human TET Oxygenases to the Oncometabolite 2-Hydroxyglutarate

doi: 10.1021/acs.jmedchem.3c01820

Figure Lengend Snippet: Results of Inhibitors Screened against the Human TETs a

Article Snippet: IOX1, IOX2, ML324, KDMOAM25, succinate, fumarate, 2OG, dimethylpyridine-2,4-dicarboxylate, dimethyl 2-oxoglutarate, dimethyl succinate, dimethyl fumarate, and DMOG were purchased from Sigma-Aldrich, while IOX3, IOX4, Roxadustat, Vadadustat, Panobinostat, disodium 2 S/2R -hydroxyglutarate, and FG0041 were obtained from Cayman Chemical Company.

Techniques: Amplified Luminescent Proximity Homogenous Assay

Journal: Annals of Translational Medicine

Article Title: Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis

doi: 10.21037/atm.2019.12.18

Figure Lengend Snippet: Characteristic studies of meta-analysis

Article Snippet: Because two studies showed results of the same cohort, 3 articles were finally included for meta-analysis. table ft1 table-wrap mode="anchored" t5 caption a7 Study Sample size Male ratio % Mean age, y CKD stage Usage of iron Use of EPO Company Dosage of roxadustat Duration of treatment Besarab 2015 88 subjects/28 controls 42.2 65.8 [47 – 82] 3 to 4 Oral only No FibroGen 0.7 g, 1.0, 1.5 and 2.0 mg/kg at BIW or TIW 29 days for BIW and 26 days for TIW Chen 2017 61 subjects/30 controls 28.6 49.7±13.2 1 to 4 Oral only No FibroGen low- (1.1 – 1.75 mg/kg) and high-dose (1.50 – 2.25mg/kg) TIW 8 weeks Akizawa 2019 80 subjects/27 controls 46.7 63.8±9.2 2 to 5 Oral was allowed and intravenous iron was used if TSAT <5% and ferritin <30 ng/mL No Astellas 50, 70 and 100 mg TIW in fixed-dose period, and adjusted dose in titration period 6 weeks fixed-dose period and 18 weeks titration period Open in a separate window TIW, three times weekly; BIW, two time weekly; EPO, erythropoietin; TAST, transferrin saturation. caption a8 Characteristic studies of meta-analysis

Techniques: Titration